Oruka Therapeutics reports Q2 GAAP EPS of -$0.55
Oruka Therapeutics has announced a Q2 GAAP EPS of -$0.55, missing expectations by $0.01.
The company had cash, cash equivalents, and marketable securities of $1.1 billion as of June 30, 2026.
These funds are expected to be sufficient to fund operations through an anticipated BLA filing for ORKA-001 and continued development of ORKA-002